CareDx to Present AlloHeme Pivotal Clinical Validation Data for Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

Reuters02-03 20:05

<a href="https://laohu8.com/S/CDNA">CareDx</a> to Present AlloHeme Pivotal Clinical Validation Data for Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

CareDx Inc. has announced that pivotal clinical validation data from the ACROBAT study evaluating its AlloHeme™ test for hematologic cancer relapse detection will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, scheduled for February 4-7, 2026, in Salt Lake City, Utah. The study is a prospective, multi-center, blinded clinical trial assessing AlloHeme, an AI-powered next-generation sequencing-based peripheral blood test, for monitoring relapse after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The complete 24-month follow-up results will be presented, expanding upon previously published 18-month interim results. An investor webcast and conference call to discuss the study findings and commercial launch timeline is planned for February 12, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203634748) on February 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608873408?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608873408","market":"nz","top_or_hot":-1,"title":"CareDx to Present AlloHeme Pivotal Clinical Validation Data for Hematologic Cancer Relapse Detection at 2026 Tandem Meetings","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CDNA\">CareDx</a> to Present AlloHeme Pivotal Clinical Validation Data for Hematologic Cancer Relapse Detection at 2026 Tandem Meetings\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CareDx Inc. has announced that pivotal clinical validation data from the ACROBAT study evaluating its AlloHeme™ test for hematologic cancer relapse detection will be presented at the 2026 Tandem Meetings, Transplantation &amp; Cellular Therapy Meetings of ASTCT™ and CIBMTR®, scheduled for February 4-7, 2026, in Salt Lake City, Utah. The study is a prospective, multi-center, blinded clinical trial assessing AlloHeme, an AI-powered next-generation sequencing-based peripheral blood test, for monitoring relapse after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The complete 24-month follow-up results will be presented, expanding upon previously published 18-month interim results. An investor webcast and conference call to discuss the study findings and commercial launch timeline is planned for February 12, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203634748) on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CareDx to Present AlloHeme Pivotal Clinical Validation Data for Hematologic Cancer Relapse Detection at 2026 Tandem Meetings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCareDx to Present AlloHeme Pivotal Clinical Validation Data for Hematologic Cancer Relapse Detection at 2026 Tandem Meetings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-03 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CDNA\">CareDx</a> to Present AlloHeme Pivotal Clinical Validation Data for Hematologic Cancer Relapse Detection at 2026 Tandem Meetings\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CareDx Inc. has announced that pivotal clinical validation data from the ACROBAT study evaluating its AlloHeme™ test for hematologic cancer relapse detection will be presented at the 2026 Tandem Meetings, Transplantation &amp; Cellular Therapy Meetings of ASTCT™ and CIBMTR®, scheduled for February 4-7, 2026, in Salt Lake City, Utah. The study is a prospective, multi-center, blinded clinical trial assessing AlloHeme, an AI-powered next-generation sequencing-based peripheral blood test, for monitoring relapse after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The complete 24-month follow-up results will be presented, expanding upon previously published 18-month interim results. An investor webcast and conference call to discuss the study findings and commercial launch timeline is planned for February 12, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203634748) on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL1VD8sP:1","article_id":"2608873408","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608873408","pubTimestamp":1770120324,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CareDx Inc. has announced that pivotal clinical validation data from the ACROBAT study evaluating its AlloHeme test for hematologic cancer relapse detection will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, scheduled for February 4-7, 2026, in Salt Lake City, Utah. The study is a prospective, multi-center, blinded clinical trial assessing AlloHeme, an AI-powered next-generation sequencing-based peripheral blood test, for monitoring relapse after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia  and myelodysplastic syndromes . The complete 24-month follow-up results will be presented, expanding upon previously published 18-month interim results. An investor webcast and conference call to discuss the study findings and commercial launch timeline is planned for February 12, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PU","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CDNA":"CareDx"},"translate_title":"CareDx将在2026年串联会议上展示用于血液癌症复发检测的同种异体血红素关键临床验证数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDNA":0.9},"content_text":"CareDx to Present AlloHeme Pivotal Clinical Validation Data for Hematologic Cancer Relapse Detection at 2026 Tandem Meetings\n    \n\n        CareDx Inc. has announced that pivotal clinical validation data from the ACROBAT study evaluating its AlloHeme™ test for hematologic cancer relapse detection will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, scheduled for February 4-7, 2026, in Salt Lake City, Utah. The study is a prospective, multi-center, blinded clinical trial assessing AlloHeme, an AI-powered next-generation sequencing-based peripheral blood test, for monitoring relapse after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The complete 24-month follow-up results will be presented, expanding upon previously published 18-month interim results. An investor webcast and conference call to discuss the study findings and commercial launch timeline is planned for February 12, 2025.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260203634748) on February 03, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608873408","isCrawlerRequest":true}